Early initiation of sacubitril/valsartan in patients with chronic heart failure after acute decompensation: a case series analysis
D Acanfora, P Scicchitano, C Acanfora… - Clinical Drug …, 2020 - Springer
Abstract Background and Objective Sacubitril/valsartan improved the prognosis of patients
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis
D Acanfora, P Scicchitano, C Acanfora… - Clinical Drug …, 2020 - search.proquest.com
Abstract Background and Objective Sacubitril/valsartan improved the prognosis of patients
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis
D Acanfora, P Scicchitano, C Acanfora… - CLINICAL DRUG …, 2020 - iris.unicampus.it
Background and Objective Sacubitril/valsartan improved the prognosis of patients with heart
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis
D Acanfora, P Scicchitano, C Acanfora… - CLINICAL DRUG …, 2020 - ricerca.uniba.it
Abstract Background and Objective Sacubitril/valsartan improved the prognosis of patients
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
with heart failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis
D Acanfora, P Scicchitano… - Clinical drug …, 2020 - pubmed.ncbi.nlm.nih.gov
Background and objective Sacubitril/valsartan improved the prognosis of patients with heart
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.
D Acanfora, P Scicchitano, C Acanfora… - Clinical Drug …, 2020 - europepmc.org
Methods Patients admitted for acute decompensated heart failure to the Department of
Internal Medicine of Telese Terme Hospital and Cardiovascular Department, University of …
Internal Medicine of Telese Terme Hospital and Cardiovascular Department, University of …
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis
D Acanfora, P Scicchitano, C Acanfora… - CLINICAL DRUG …, 2020 - iris.unicampus.it
Background and Objective Sacubitril/valsartan improved the prognosis of patients with heart
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …
failure with reduced ejection fraction in the PARADIGM-HF study. Recently, the TRANSITION …